Nurix Therapeutics, Inc. 10-Q

Item 1. Financial statements. Nurix Therapeutics, Inc. Condensed c onsolidated balance sheets (in thousands, except share and per share amounts) (unaudited) August 31, November 30, 2020 2019 Assets Current assets: Cash and cash equivalents $ 265,527 $ 34,816 Short-term investments 88,716 2,904 Income tax receivable 3,856 — Prepaid expenses and other current assets 5,990 1,634 Total current assets 364,089 39,354 Long-term investments 40,898 506 Property and equipment, net 6,532 3,871 Restricted cash 170 170 Other assets 185 147 Total assets $ 411,874 $ 44,048 Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities: Accounts payable $ 3,611 $ 1,598 Accrued and other current liabilities 7,102 4,927 Deferred revenue, current 30,299 9,612 Total current liabilities 41,012 16,137 Deferred revenue, net of current portion 62,374 35,693 Other long-term liabilities 868 1,737 Total liabilities 104,254 53,567 Commitments and contingencies (Note 6) Redeemable convertible preferred stock, $0.001 par value—0 and 48,441,667 shares authorized as of August 31, 2020 and November 30, 2019, respectively; 0 and 12,813,887 shares issued and outstanding (liquidation value—$0 and $48,383) as of August 31, 2020 and November 30, 2019, respectively — 48,195 Stockholders’ equity (deficit): Preferred stock, $0.001 par value—10,000,000 and 0 shares authorized as of August 31, 2020 and November 30, 2019, respectively; 0 shares issued and outstanding as of August 31, 2020 and November 30, 2019, respectively — — Common stock, $0.001 par value—500,000,000 and 65,000,000 shares authorized as of August 31, 2020 and November 30, 2019, respectively; 38,845,196 and 3,595,334 shares issued and outstanding as of August 31, 2020 and November 30, 2019, respectively 39 4 Additional paid-in-capital 391,227 2,740 Accumulated other comprehensive income (loss) 138 (2 ) Accumulated deficit (83,784 ) (60,456 ) Total stockholders’ equity (deficit) 307,620 (57,714 ) Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) $ 411,874 $ 44,048 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 Nurix Therapeutics, Inc. Condensed c onsolidated statements of operations (in thousands, except share and per share amounts) (unaudited) Three Months Ended Nine Months Ended August 31, August 31, 2020 2019 2020 2019 Collaboration revenue (1) $ 4,085 $ 10,580 $ 11,131 $ 29,253 Operating expenses: Research and development 18,939 11,008 46,049 32,201 General and administrative 4,338 2,184 10,057 5,724 Total operating expenses 23,277 13,192 56,106 37,925 Loss from operations (19,192 ) (2,612 ) (44,975 ) (8,672 ) Interest and other income, net 675 195 1,071 521 Loss before provision (benefit) for income taxes (18,517 ) (2,417 ) (43,904 ) (8,151 ) Provision (benefit) for income taxes — 10 (20,576 ) 29 Net loss $ (18,517 ) $ (2,427 ) $ (23,328 ) $ (8,180 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.59 ) $ (0.66 ) $ (0.84 ) $ (2.38 ) Weighted-average number of shares outstanding, basic and diluted 31,383,936 3,667,335 27,688,972 3,433,809 (1) Collaboration revenue for the three months ended August 31, 2020 and 2019 includes related party revenue of $0 and $9.7 million, respectively. Collaboration revenue for the nine months ended August 31, 2020 and 2019 includes related party revenue of $0 and $28.4 million, respectively. The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 Nurix Therapeutics, Inc. Condensed consolidated s tatements of comprehensive loss (in thousands) (unaudited) Three Months Ended Nine Months Ended August 31, August 31, 2020 2019 2020 2019 Net loss $ (18,517 ) $ (2,427 ) $ (23,328 ) $ (8,180 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments (1 ) (1 ) 140 4 Total comprehensive loss $ (18,518 ) $ (2,428 ) $ (23,188 ) $ (8,176 ) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Nurix Therapeutics, Inc. Condensed consolidated statements of redeemable convertible preferred stock and stockholders’ equity (deficit) (in thousands, except share amounts) (unaudited) Redeemable convertible preferred stock Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ equity Shares Amount Shares Amount capital income (loss) deficit (deficit) Balance as of November 30, 2019 12,813,887 $ 48,195 3,595,334 $ 4 $ 2,740 $ (2 ) $ (60,456 ) $ (57,714 ) Exercise of stock options — — 72,570 — 37 — — 37 Repurchase of unvested early exercised stock options — — (867 ) — — — — — Vesting of early-exercised stock options — — — — 31 — — 31 Stock-based compensation — — — — 176 — — 176 Unrealized gain on available-for-sale investments — — — — — 59 — 59 Net loss — — — — — — (12,391 ) (12,391 ) Balance as of February 29, 2020 12,813,887 48,195 3,667,037 4 2,984 57 (72,847 ) (69,802 ) Issuance of Series D redeemable convertible preferred stock at $12.75 per share, net of issuance costs of $336 9,431,364 119,914 — — — — — — Exercise of stock options — — 125,708 — 118 — — 118 Vesting of early-exercised stock options — — — — 22 — — 22 Stock-based compensation — — — — 474 — — 474 Unrealized gain on available-for-sale investments — — — — — 82 — 82 Net income — — — — — — 7,580 7,580 Balance as of May 31, 2020 22,245,251 168,109 3,792,745 4 3,598 139 (65,267 ) (61,526 ) Conversion of redeemable convertible preferred stock into common stock (22,245,251 ) (168,109 ) 22,245,251 22 168,087 — — 168,109 Issuance of common stock upon initial public offering, net of offering cost of $20,308 — — 12,550,000 13 218,130 — — 218,143 Exercise of stock options — — 258,182 — 262 — — 262 Repurchase of unvested early exercised stock options — — (982 ) — — — — — Vesting of early-exercised stock options — — — — 35 — — 35 Stock-based compensation — — — — 1,115 — — 1,115 Unrealized loss on available-for-sale investments — — — — — (1 ) — (1 ) Net loss — — — — — — (18,517 ) (18,517 ) Balance as of August 31, 2020 — $ — 38,845,196 $ 39 $ 391,227 $ 138 $ (83,784 ) $ 307,620 4 Redeemable convertible preferred stock Common stock Additional paid-in Accumulated other comprehensive Accumulated Total stockholders’ equity Shares Amount Shares Amount capital income (loss) deficit (deficit) Balance as of November 30, 2018 12,813,887 $ 48,195 3,452,653 $ 4 $ 1,910 $ (4 ) $ (38,757 ) $ (36,847 ) Exercise of stock options — — 15,985 — 8 — — 8 Vesting of early-exercised stock options — — — — 53 — — 53 Stock-based compensation — — — — 102 — — 102 Unrealized gain on available-for-sale investments — — — — — 5 — 5 Net loss — — — — — — (2,685 ) (2,685 ) Balance as of February 28, 2019 12,813,887 48,195 3,468,638 4 2,073 1 (41,442 ) (39,364 ) Exercise of stock options — — 67,026 — 47 — — 47 Repurchase of unvested early exercised stock options — — (7,882 ) — — — — — Vesting of early-exercised stock options — — — — 83 — — 83 Stock-based compensation — — — — 105 — — 105 Net loss — — — — — — (3,068 ) (3,068 ) Balance as of May 31, 2019 12,813,887 48,195 3,527,782 4 2,308 1 (44,510 ) (42,197 ) Exercise of stock options — — 1,229 — 1 — — 1 Repurchase of unvested early exercised stock options — — (7,913 ) — — — — — Vesting of early-exercised stock options — — — — 48 — — 48 Stock-based compensation — — — — 136 — — 136 Unrealized loss on available-for-sale investments — — — — — (1 ) — (1 ) Net loss — — — — — — (2,427 ) (2,427 ) Balance as of August 31, 2019 12,813,887 $ 48,195 3,521,098 $ 4 $ 2,493 $ — $ (46,937 ) $ (44,440 ) The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 5 Nurix Therapeutics, Inc. Condensed c onsolidated statements of cash flows (in thousands) (unaudited) Nine Months Ended August 31, 2020 2019 Cash flows from operating activities Net loss $ (23,328 ) $ (8,180 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 1,536 1,805 Stock-based compensation 1,765 343 Net amortization (accretion) of premium (discount) 130 (109 ) Changes in operating assets and liabilities: Income tax receivable (3,856 ) — Prepaid expenses and other current assets (4,394 ) (283 ) Accounts payable 602 259 Deferred revenue 47,368 18,747 Accrued and other liabilities 579 767 Net cash provided by operating activities 20,402 13,349 Cash flows from investing activities Purchases of investments (141,067 ) (5,939 ) Maturities of investments 14,873 19,500 Purchases of property and equipment (3,647 ) (698 ) Net cash provided by (used in) investing activities (129,841 ) 12,863 Cash flows from financing activities Proceeds from issuance of common stock upon initial public offering, net of offering costs 219,301 — Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 119,914 — Proceeds from exercise of stock options 937 62 Repurchase of unvested early exercised stock options (2 ) (16 ) Net cash provided by financing activities 340,150 46 Net increase in cash, cash equivalents and restricted cash 230,711 26,258 Cash, cash equivalents and restricted cash at beginning of period 34,986 25,761 Cash, cash equivalents and restricted cash at end of period $ 265,697 $ 52,019 Supplemental disclosures of noncash investing and financing activities: Additions to property and equipment included in accounts payable and accrued liabilities $ 550 $ 75 Vesting of early exercised stock options $ 88 $ 184 Offering costs included in accounts payable and accrued liabilities $ 1,158 $ — Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering $ 168,109 $ — The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Nurix Therapeutics, Inc. Notes to unaudited condensed c onsolidated financial statements 1. The company Description of business Nurix Therapeutics, Inc. (the Company) previously known as Nurix, Inc., was incorporated in the state of Delaware on August 27, 2009 and is headquartered in San Francisco, California. The Company is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging the Company’s expertise in E3 ligases together with its proprietary DNA-encoded libraries, the Company has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. The Company’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels to treat disease. The Company wholly owns a subsidiary, DeCART Therapeutics Inc. (DeCART), which was incorporated in the state of Delaware on June 22, 2020 and holds a license to three of the Company’s compounds, including NX-0255, for drug-enhanced isolation of T cells nonexclusively with respect to one chimeric antigen receptor T cell (CAR-T) therapy target and exclusively with respect to three novel CAR-T therapy targets. Reverse stock split On July 17, 2020, the Company filed an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock and redeemable convertible preferred stock, each on a 1-for-3 basis (reverse stock split). The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented. Initial public offering On July 23, 2020, the Company’s registration statement on Form S-1 (File No. 333-239651) relating to its initial public offering (IPO) of common stock became effective. The IPO closed on July 28, 2020 at which time the Company issued 11,000,000 shares of its common stock at a price to the public of $19.00 per share. In addition, the underwriters exercised their option to purchase an additional 1,550,000 shares of the Company’s common stock on July 31, 2020, and this transaction closed on August 4, 2020. Immediately prior to the closing of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock automatically converted into 22,245,251 shares of common stock. Net proceeds from the IPO, including the exercise of the underwriters’ option to purchase additional shares, were $218.1 million, after deducting underwriting discounts and commissions of $16.7 million and expenses of $3.6 million. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. In connection with the closing of the IPO, the Company restated its Restated Certificate of Incorporation to change the authorized capital stock to 500,000,000 shares designated as common stock, and 10,000,000 shares designated as preferred stock, all with a par value of $0.001 per share. Liquidity The Company’s operations have historically been financed through the issuance of common and redeemable convertible preferred stock and proceeds received under the Company’s collaboration and license agreements. Since inception, the Company has generally incurred significant losses and negative net cash flows from operations. During the nine months ended August 31, 2020, the Company incurred a net loss of $23.3 million and had positive net cash flows from operating activities of $20.4 million. The Company had an accumulated deficit as of August 31, 2020 of $83.8 million and will require substantial additional capital for research and development activities. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Management believes that its cash, cash equivalents and investments are sufficient to continue operating activities for at least 12 months following the issuance date of these condensed consolidated financial statements. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development and payments the Company may receive under its collaboration agreements with Sanofi S.A. (Sanofi) and Gilead Sciences, Inc. (Gilead) or future collaboration agreements, if any. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms 7 acceptable to the Company if at all. If additional capital is not available, f ailure to generate su fficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. Other risks and uncertainties The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on its future financial position or results of operations: risks related to the successful discovery and development of its product candidates, ability to raise additional capital, development of new technological innovations by its competitors and delay or inability to obtain drug substance and finished drug product from the Company’s third-party contract manufacturers necessary for the Company’s product candidates, including due to the impact of the current coronavirus (COVID-19) pandemic, protection of intellectual property rights, litigation or claims against the Company based on intellectual property rights and regulatory clearance and market acceptance for any of the Company’s products candidates for which the Company receives marketing approval. Moreover, the current COVID-19 pandemic, which is impacting worldwide economic activity, poses the risk that the Company or its employees, contractors, suppliers and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the COVID-19 pandemic will impact the Company’s business will depend on future developments that are highly uncertain and cannot be predicted at this time. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s financial statements is highly uncertain and subject to change. Management considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s condensed consolidated financial statements as of and for the three and nine months ended August 31, 2020; however, actual results could differ from those estimates and there may be changes to management’s estimates in future periods. The Company relies on single source manufacturers and suppliers for the supply of its product candidates. Disruption from these manufacturers or suppliers would have a negative impact on the Company’s business, financial position and results of operations. 2. Summary of significant accounting policies Basis of presentation The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Principles of consolidation The accompanying condensed consolidated financial statements include the accounts of Nurix Therapeutics, Inc. and its wholly owned subsidiary, DeCART. All intercompany balances and transactions have been eliminated in consolidation. Unaudited interim condensed consolidated financial statements The condensed consolidated balance sheet as of August 31, 2020 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and redeemable convertible preferred stock and stockholders’ equity (deficit) for the three and nine months ended August 31, 2020 and 2019 are unaudited. Except for the adoption of Topic 606, Revenue from Contracts with Customers , as described in the revenue recognition policy within this same note, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of August 31, 2020 and its results for the three and nine months ended August 31, 2020 and 2019. The financial data and the other financial information disclosed in these notes related to the three and nine months ended August 31, 2020 and 2019 are also unaudited. The condensed consolidated balance sheet as of November 30, 2019, included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim condensed consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements 8 and the notes thereto, which are included in the Company’s prospectus for the IPO dated July 23, 2020 and filed with the SEC on July 24, 2020 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended . The results of operations for the three and nine months ended August 31, 2020 are not necessarily indicative of the results to be expected for the year ending Novembe r 30, 2020 , or for any other future annual or interim period. Segments The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews consolidated financial information on a company-wide basis for purposes of allocating resources and assessing financial performance. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Deferred offering costs The Company capitalizes within other assets certain legal, accounting and other third-party fees that are directly related to the Company’s in-process equity financings, including the IPO, until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the carrying value of redeemable convertible preferred stock or, for issuances of common stock, in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. There were no deferred offering costs capitalized as of August 31, 2020 and November 30, 2019. Upon the closing of the IPO on July 28, 2020, the offering costs of $20.3 million were recorded in stockholder’s equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Revenue recognition Prior to December 1, 2019, the Company recognized revenue in accordance with the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) 605, Revenue Recognition . Accordingly, revenue is recognized for each unit of accounting when all of the following criteria are met: • Persuasive evidence of an arrangement exists; • Delivery has occurred or services have been rendered; • The seller’s price to the buyer is fixed or determinable; and • Collectibility is reasonably assured. The Company evaluates multiple element arrangements to determine if each deliverable represents a separate unit of accounting based on the following criteria: • Delivered item or items have value to the customer on a standalone basis, and • If the arrangement includes a general right of return relative to the delivered item or items, delivery or performance of the undelivered item or items is considered probable and substantially in control of the Company. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price methodology in accordance with the selling price hierarchy, which includes vendor-specific objective evidence (VSOE) of selling price, if available, or third-party evidence of selling price if VSOE is not available, or the best estimate of selling price, if neither VSOE nor third-party evidence is available. The provisions of ASC 605 are then applied to each unit of accounting to determine the appropriate revenue recognition. In the event that a deliverable of a multiple element arrangement does not represent a separate unit of accounting, primarily because a deliverable does not provide value on a standalone basis, the Company recognizes revenue from the combined unit of accounting using the input/proportional performance approach as research is delivered or on a straight-line basis over the estimated period of performance when there is no discernable pattern of performance. 9 The Company evaluates potential milestone payments associated with research and development arrangements in accordance with ASC 605-28, Milestone Method. Under the milestone method, the Compan y may recognize revenue contingent upon the achievement of a milestone in its entirety in the period in which the milestone is achieved, only if the milestone meets all the criteria within the guidance to be considered a substantive milestone . The Company evaluates each contingent payment on an individual basis to determine whether they are considered substantive milestones, specifically reviewing factors such as the degree of certainty in achieving the milestone, the research and development risk and other risks that must be overcome to achieve the milestone, as well as the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s per formance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. Revenues from milestones, if they are nonrefun dable and deemed substantive, are recognized upon achievement of the milestones. To the extent that non-substantive milestones are achieved, and the Company has remaining deliverables, milestone payments are deferred and recognized as revenue over the estimated remaining performance period using the appropriate measure of progress as determined for each agreement. The Company recognizes revenue associated with the non-substantive milestones upon achievement of the milestone if the Company has no remaining deliverables. During the nine months ended November 30, 2019, no milestone payments were received, no milestone revenues were recognized and no milestones were considered substantive. Effective December 1, 2019, the Company adopted Topic 606, Revenue from Contracts with Customers using the modified retrospective method, which was only applied to contracts that were not completed as of the adoption date. As of the adoption date, the Company had only one contract, a collaboration agreement with Gilead, not completed. Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company enters into collaboration agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations. Research and collaboration licenses : If a license is determined to be distinct from the other promises identified in the arrangement, the Company recognizes revenue from upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments : At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone amount is included in the transaction price. 10 S ales-based milestones and royalties : For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate t o, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resu lting from its collaboration arrangements. Customer options : Customer options, such as options granted to allow a licensee to extend a license or research term, to select additional research targets or to choose to research, develop and commercialize licensed compounds are evaluated at contract inception to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the standalone selling price. As a practical alternative to estimating the standalone selling price of a material right when the underlying goods or services are both (i) similar to the original goods or services in the contract and (ii) provided in accordance with the terms of the original contract, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires. Deferred revenue, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the condensed consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation. All revenue was derived from customers located in the United States during the three and nine months ended August 31, 2020 and 2019. Research and development expenses The Company expenses all research and development costs as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. The Company records accrued expenses for estimated costs of research and development activities conducted by third-party service providers, which include preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company estimates the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. The Company makes significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, the Company adjusts its accrued estimates. The Company’s accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party service providers. The Company records advance payments to service providers as prepaid assets, which are expensed as the contracted services are performed. Stock-based compensation The Company accounts for stock-based compensation using a fair value-based method, which requires the recognition of compensation expense for costs related to all stock-based payments including stock options and purchase rights under the employee stock purchase plan. The Company estimates the fair value of stock-based payment awards on the date of grant using the Black-Scholes option pricing model. The model requires management to make a number of assumptions including expected volatility, expected term, risk-free interest rate and expected dividend yield. Prior to its IPO, the fair value of the Company’s common stock was determined by the Company’s board of directors with assistance from management and an independent third party valuation firm, using significant judgment and several factors including important developments in the Company’s operations, sales of preferred stock and the lack of liquidity of the common stock. Subsequent to the IPO, the Company determines the fair value using the market closing price of the Company’s common stock on the date of grant. For stock-based payments with service conditions only, the Company uses the straight-line method to allocate compensation cost to reporting periods over the requisite service period, which is generally the vesting period. Subsequent to the adoption of ASU 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting as of December 1, 2019, 11 stock-based compensation expense for non-employee stock-based awards is also measured based on the grant date fair value with the estimated fair value expensed over the period for which th e non-employee is required to provide service in exchange for the award. For stock-based payments with performance conditions, the Company evaluates the probability of achieving performance conditions at each reporting date. The Company begins to recognize compensation cost using an accelerated attribution method when it is deemed probable that the performance condition will be met. The Company accounts for forfeitures as they occur. Restricted cash The Company had $170,000 of restricted cash recorded as a non-current asset as of August 31, 2020 and November 30, 2019. Restricted cash consisted of $100,000 that serves as collateral for a business credit card account and $70,000 for a letter of credit required under a facility operating lease executed in 2014. These balances are included within the cash, cash equivalents and restricted cash balance in the accompanying condensed consolidated statements of cash flows. Concentration of credit risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and investments. The Company’s investments consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits, but minimal credit risk exists. The Company invests its cash equivalents in highly rated money market funds. The Company has not experienced any credit losses on its deposits of cash and cash equivalents. Cash and cash equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents, which consist primarily of money market funds, are stated at fair value. Cash, cash equivalents and restricted cash as reported within the condensed consolidated statements of cash flows as of August 31, 2020 and 2019 and November 30, 2019 and 2018 consisted of the following (in thousands): August 31, November 30, 2020 2019 2019 2018 Cash and cash equivalents $ 265,527 $ 51,849 $ 34,816 $ 25,591 Restricted cash 170 170 170 170 Cash, cash equivalents and restricted cash $ 265,697 $ 52,019 $ 34,986 $ 25,761 Investments Investments consist of money market funds, U.S. Treasuries, corporate debt securities, U.S. government agency securities, corporate commercial paper and municipal securities. All of the Company’s investments are classified as available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term investments or long-term investments. Management determines the appropriate classification of the investments at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. Investments with contractual maturities greater than 12 months are considered long-term investments. Unrealized gains and losses on available-for-sale investments are reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity (deficit). Investments are regularly reviewed for other-than-temporary declines in fair value. The review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of investments in an unrealized loss position, the severity and duration of the unrealized losses, and whether it is more likely than not that the Company will be required to sell the investments before the recovery of their amortized cost basis. The cost of investments sold is based on the specific identification method. Fair value of financial instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, investments, accounts payable and accrued liabilities included in the Company’s condensed consolidated financial statements approximate their fair value due to short maturities or the nature of the financial instruments. 12 Recent accounting pronouncements The Company is an “emerging growth company” (EGC), as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act). Under the JOBS Act, EGCs can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an EGC or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of the public company effective dates. Adopted recent accounting pronouncements In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) and has subsequently issued a number of amendments to Topic 606. As amended, Topic 606 provides a single comprehensive model to be used in the accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. Topic 606 also requires entities to disclose both qualitative and quantitative information that enables users of financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers, including disclosure of significant judgments affecting the recognition of revenue. The Company adopted Topic 606 as of December 1, 2019 using the modified retrospective method, which was only applied to contracts that were not completed as of the adoption date. As of the adoption date, the Company had only one contract, the collaboration agreement with Gilead, not completed. The Company did not elect to use any of the practical expedients permitted related to adoption. The adoption of Topic 606 did not result in a cumulative adjustment to the accumulated deficit as it did not change the timing and pattern of revenue recognition for the collaboration agreement with Gilead. For the nine months ended August 31, 2020, there would have been no difference between the revenue recognized under Topic 606 and the revenue recognized under ASC 605 for the collaboration agreement with Gilead. The adoption of Topic 606 did not have a material impact on the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting (ASU 2018-07), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. An entity should apply the requirements of Topic 718 to non-employee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). ASU 2018-07 is effective for annual periods beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company adopted ASU 2018-07 as of December 1, 2019. The adoption did not have a material impact on the Company’s condensed consolidated financial statements. Recent accounting pronouncements not yet adopted In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU 2016-02) , which for operating leases requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of lease payments, in its balance sheet. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. ASU 2016-02 is effective for annual periods beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements. In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectibility. ASU 2016-13 also eliminates the concept of “other-than-temporary” impairment when evaluating available-for-sale debt investments and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt investments rather than an other-than-temporary impairment that reduces the cost basis of the investment. ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those annual periods. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which modifies the disclosure requirements on fair 13 value measurements by removing the requirement to discl ose amounts of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation process for Level 3 fair value measurements, among other modifications to fair value meas urement disclosure requirements. ASU 2018-13 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. Early adoption is permitted. The Company does not expect the adoption to have a material impact on its financial statements. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. ASU 2018-18 is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. ASU 2018-18 requires retrospective adoption to the date the Company adopted Topic 606 by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company does not expect the adoption to have a material impact on its financial statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 is effective for annual periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its financial statements. 3. Collaboration agreements Celgene (a related party) In September 2015, the Company entered into a collaboration agreement with Celgene Corporation (the Celgene Agreement and Celgene, respectively), which was later acquired by Bristol-Myers Squibb Company (BMS) in November 2019, with an initial research term of four years for the discovery, development and commercialization of novel small molecule therapeutics in oncology, inflammation and immunology. Under the terms of the Celgene Agreement, the Company received an upfront payment of $150.0 million in September 2015. In addition, in September 2015, Celgene purchased 1,622,222 shares of Series C redeemable convertible preferred stock at a price of $10.50 per share, resulting in net proceeds of $17.0 million. As of November 30, 2019, BMS held approximately 10% of total shares outstanding on an as-converted basis. In January 2019, Celgene and BMS entered into a definitive merger agreement pursuant to which Celgene agreed to be acquired by BMS. Based on the Company’s request for notification of the future disposition of the agreement, in June 2019, Celgene notified the Company that it was terminating the Celgene Agreement. Upon termination of the Celgene Agreement in June 2019, any rights that Celgene had under the agreement reverted to the Company and no termination payments were due or payable. The Company determined it had no remaining deliverables to be performed under the Celgene Agreement and as a result recognized all remaining deferred revenue in June 2019. Collaboration revenue related to the Celgene Agreement was $0 and $9.7 million for the three months ended August 31, 2020 and 2019, respectively, and $0 and $28.4 million for the nine months ended August 31, 2020 and 2019, respectively. As of August 31, 2020 and November 30, 2019, deferred revenue of $0 was recorded on the condensed consolidated balance sheet. Gilead In June 2019, the Company entered into a global strategic collaboration agreement with Gilead, which was amended in August 2019 (the Gilead Agreement), to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using the Company’s DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets. 14 Under the Gilead Agreement, Gilead has the option to license drug candidat es directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commercialization of product candidates resulting from the collaboration. The Company retains the option to co-develop and co-promote, un der a profit share structure, up to two product candidates in the United States, provided that the Company may only exercise such option once per licensed product and Gilead retains the right to veto the Company’s option selection for any one product candi date of its choice. The collaboration excludes the Company’s current internal protein degradation programs for which the Company retain s all rights, and also excludes the Company’s future internal programs, provided that the Company has distinguished futur e programs as excluded from the scope of the collaboration. Over time, Gilead may elect to replace the initial drug targets with other drug targets. For drug targets that are subject to the collaboration, the Company is obligated to use commercially reasonable efforts to undertake a research program in accordance with a research plan agreed to by the parties and established on a target-by-target basis. The Company has primary responsibility under the agreement for performing preclinical research activities (including target validation, drug discovery, identification or synthesis) pursuant to a research plan. Each party will bear its own costs in the conduct of research activities. Gilead will be responsible for any development, commercialization and manufacturing activities, unless the Company exercises its co-development and co-promotion option. For those programs that the Company exercises its option to co-develop and co-promote, the Company and Gilead will split U.S. development costs as well as U.S. profits and losses evenly, and the Company will be eligible to receive royalties on net ex-U.S. sales and reduced milestone payments. Upon signing the Gilead Agreement, Gilead agreed to pay the Company an upfront payment of $45.0 million plus $3.0 million in additional fees, and the Company is eligible to receive up to approximately $2.3 billion in total additional payments, including up to $700.0 million upon the achievement of specified development milestones, up to $1.5 billion upon the achievement of specified sales milestones, subject to reduction for any product for which the Company exercises its option to co-develop and co-promote, and up to $145.8 million in certain additional fees related to target licensing, reservation and selection and research term extensions. In addition, the Company is eligible to receive tiered royalties from mid-single digit to low tens percentages on annual net sales from any commercial products directed to the optioned collaboration targets, subject to certain reductions and excluding sales in the United States of any products for which the Company exercises its option to co-develop and co-promote, for which the Company and Gilead share profits and losses evenly. In June 2019, the Company received the $45.0 million upfront payment and $3.0 million in additional fees. In February 2020, the Company achieved a research milestone, resulting in a $2.5 million additional payment, which was received by the Company in April 2020. In May 2020, the Company recorded $1.0 million in additional fees related to certain target reservation, which was received in June 2020. Subject to earlier expiration in certain circumstances, the Gilead Agreement expires on a licensed product-by-licensed product and country-by-country basis upon the later of (1) the expiration of the last to expire patent with a valid claim covering the applicable licensed product in the applicable country, (2) the expiration of any regulatory exclusivity for the applicable licensed product in the applicable country or (3) ten years after the first commercial sale of the applicable licensed product in the applicable country covered by the Gilead Agreement, provided that the term for any profit-shared licensed product in the United States will expire upon the expiration or termination of the applicable profit-share term as set forth in an applicable profit-share agreement to be negotiated upon the Company’s exercise of its option to co-develop and co-promote such licensed product. If Gilead does not exercise an option to license a drug candidate, then the Gilead Agreement will terminate at the end of the last to expire option period. The Company identified the following promises in the Gilead Agreement: (1) the research licenses, (2) the research services, including selection campaign research services for certain replacement targets and (3) the obligation to share information during the research and to participate in the joint research committee and joint steering committee. The Company determined that the research licenses are not capable of being distinct due to the specialized nature of the research services to be provided by the Company, and, accordingly, this promise was combined with the research services and participation in the joint research committee as one single performance obligation. The Company concluded that, at the inception of the Gilead Agreement, Gilead’s options to obtain an exclusive development, manufacturing and commercialization license for each collaboration target, to extend the five-year research term and to perform selection campaign research services for certain replacement targets do not represent material rights and are not considered performance obligations because they do not contain a significant and incremental discount. The Company concluded that Gilead’s target reservation right is not a performance obligation as it does not require any specific action from the Company and it is rather an exclusivity right and an attribute of other performance obligations in the Gilead Agreement, such as the research licenses. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Certain milestones and additional fees were considered variable consideration, which were not included in the transaction price based on the most likely amount method as of August 31, 2020. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the transaction price at the inception of the Gilead Agreement consists of the upfront payment of $45.0 million and $3.0 million in additional fees. Upon the achievement of a research milestone in February 2020 and additional fees related to a target reservation in 15 May 2020, $3.5 million in variable consideration was added to the transaction price, and a cumulative effect was recorded as revenue in the period the transaction price increased . The transaction price is recognized as collaboration revenue using the cost-based input method over the estimated contract term of five years. The contract term was determined to be the five-year initial research term which represents the estimated timing of completion of the identified deliverables. Additio nally, the Company considered the impact of Gilead terminating the agreement prior to the completion of the research services during the initial five-year research term and determined that there were significant economic costs to Gilead for doing so, and a s such, did not adjust the contract term. Using the cost-based input method, which the Company determined most faithfully depicts the transfer of its performance obligation to Gilead, the Company recognizes revenue based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. These actual costs consist primarily of internal FTE efforts and third party contract costs related to the Gilead Agreement. For the three and nine months ended August 31, 2020, the Company recognized collaboration revenue related to the Gilead Agreement of $2.1 million and $6.9 million, respectively, of which $1.9 million and $6.0 million, respectively, were included in deferred revenue as of November 30, 2019, and $0.2 million and $0.7 million, respectively, were related to performance obligation satisfied in previous periods. For the three and nine months ended August 31, 2019, the Company recognized revenue related to the Gilead Agreement of $0.8 million and $0.8 million, respectively. As of August 31, 2020, $41.9 million was recorded as deferred revenue, of which $12.5 million was current, on the condensed consolidated balance sheet related to the Gilead Agreement. Sanofi In December 2019, the Company entered into a strategic collaboration with Sanofi, which became effective in January 2020 (the Sanofi Agreement), to discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas using the Company’s DELigase platform to identify small molecules designed to induce degradation of three specified initial drug targets, with an option by Sanofi to expand to a total of five targets. Over time and subject to certain limitations, Sanofi may elect to replace the drug targets with other reserved targets. Under the Sanofi Agreement, Sanofi has exclusive rights and is responsible for the clinical development, commercialization and manufacture of product candidates resulting from the collaboration while the Company retains the option to co-develop, co-promote and co-commercialize up to two targets, one of which must be selected from a list of targets designated at the execution of the Sanofi Agreement and one of which must be selected from targets identified by Sanofi in the future. The Company’s right to exercise its option to co-develop, co-promote and co-commercialize a given target is dependent on its ability to demonstrate, within a given timeframe, that it has sufficient cash resources and personnel to commercialize the product. The collaboration excludes the Company’s current internal protein degradation programs for which it retains all rights, and also excludes future internal programs, provided that the Company distinguished future programs as excluded from the scope of the collaboration. For drug targets that are subject to the collaboration, the Company has primary responsibility for conducting preclinical research activities (including target validation, drug discovery, identification or synthesis) in accordance with the applicable research plan agreed to by the parties and established on a target-by-target basis. The Company is obligated to use commercially reasonable efforts to identify relevant target binders and chimeric targeting molecules in order to identify development candidates. Subject to certain exceptions, each party will bear its own costs in the conduct of such research. Sanofi will be responsible for any development and commercialization activities, unless the Company exercises its co-development and co-promotion option. For those programs that the Company exercises its option to co-develop, co-promote and co-commercialize, the Company will be responsible for a portion of the U.S. development costs, and the parties will split U.S. profits and losses evenly and the Company will be eligible to receive royalties on ex-U.S. net sales and reduced milestone payments on such optioned products. Upon signing the Sanofi Agreement, Sanofi agreed to pay an upfront payment of $55.0 million, which was received in January 2020, and the Company is eligible to receive additional payments if Sanofi exercises its option to expand the number of targets beyond the initial targets included in the collaboration or exercises an option to extend the license term with respect to a particular target. In addition, the Company is eligible to receive up to approximately $2.5 billion in total payments, including payments of up to $500.0 million upon the achievement of specified development milestones, up to $625.0 million upon the achievement of specified regulatory milestones and up to $1.3 billion upon the achievement of certain sales milestones, as well as up to $170.1 million in certain additional fees related to target licensing and reservation. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on annual net sales of any commercial products that may result from the collaboration, subject to certain reductions and excluding sales in the United States of any products for which the Company exercises its option to co-develop and co-promote, for which the parties share profits and losses evenly. 16 The Company identified the following promises in the Sanofi Agreement: (1) the research licenses, (2) the research services, (3) the obligation to share information during the research term and (4) the participation of alliance managers in the joint research committee and joint patent committee. The Company determined that the research licenses are not capable of being distinct due to the specialized nature of the research services to be provided by the Company, and, accordingly, this promise was combined with the research services as one single performance obligation. The Company also determined that Sanofi’s exclusive right to add up to two additional targets constitutes a material right as it represents a significant and incremental discount that Sanofi would not have received without entering into the Sanofi Agreement. The option to extend the license term does not r epresent a material right because it does not contain a significant and incremental discount . In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Milestone and additional fees were considered variable consideration, which were not included in the transaction price based on the most likely amount method as of August 31, 2020. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the transaction price consists of the upfront payment of $55.0 million at the inception of the Sanofi Agreement and as of August 31, 2020. To account for the material right related to the two additional targets, instead of determining the standalone selling price for the option directly, the Company applied the practical alternative to allocating the transaction price by determining the consideration that it expects to receive in exchange for the research activities that it expects to provide on the two additional targets for a total of five targets. The practical alternative can be applied as the research activities for the two additional targets are similar to the research activities for the initial three targets. Consequently, for the purpose of applying the practical alternative to estimating the standalone selling price of the material right, an expected consideration of $77.0 million was used for revenue recognition allocation, which represents the $55.0 million paid upfront for the three initial drug targets, and the $22.0 million for the additional consideration related to two additional targets which was included as part of applying the practical alternative, but for which the option has not been exercised. Revenue is recognized over the research term of four years, the contractual initial research period, using the cost-based input method, which the Company determined most faithfully depicts the transfer of its performance obligations to Sanofi, based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligations. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. These actual costs consist primarily of internal FTE efforts and third party contract costs related to the Sanofi Agreement. For the three and nine months ended August 31, 2020, the Company recognized collaboration revenue related to the Sanofi Agreement of $2.0 million and $4.2 million, respectively. As of August 31, 2020, $50.8 million was recorded as deferred revenue, of which $17.8 million was current, on the condensed consolidated balance sheet related to the Sanofi Agreement. 4. Condensed consolidated balance sheet components Property and equipment, net Property and equipment, net, consisted of the following (in thousands): August 31, 2020 November 30, 2019 Laboratory equipment $ 13,274 $ 10,821 Leasehold improvements 2,658 2,483 Computer equipment 745 654 Furniture and fixtures 506 478 Software 1,057 282 Internal-use software 831 156 19,071 14,874 Less: Accumulated depreciation and amortization (12,539 ) (11,003 ) $ 6,532 $ 3,871 Depreciation and amortization expense was $0.6 million and $0.6 million for the three months ended August 31, 2020 and 2019, respectively, and $1.5 million and $1.8 million for the nine months ended August 31, 2020 and 2019, respectively. All long-lived assets are maintained in the United States. 17 Accrued and other current liabilities Accrued and other current liabilities consisted of the following (in thousands): August 31, 2020 November 30, 2019 Accrued compensation $ 3,761 $ 3,751 Accrued contract research and lab supplies 1,909 322 Accrued professional services 440 512 Accrued taxes 34 33 Other 958 309 $ 7,102 $ 4,927 5. Fair value measurements In accordance with the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: Level 1—Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active; and Level 3—Inputs that are unobservable. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and considers factors specific to the asset or liability. The following tables presents the Company’s financial assets, which consist of cash equivalents and investments classified as available-for-sale investments, that are measured at fair value on a recurring basis as of August 31, 2020 and November 30, 2019 (in thousands): August 31, 2020 Level Amortized cost Unrealized gain Unrealized loss Estimated fair value Money market funds Level 1 $ 265,527 $ — $ — $ 265,527 U.S. treasury securities Level 1 31,003 37 (2 ) 31,038 Corporate debt securities Level 2 10,128 21 — 10,149 U.S. government agency securities Level 2 9,021 24 — 9,045 Corporate commercial paper Level 2 35,448 — — 35,448 Municipal securities Level 2 3,026 11 (1 ) 3,036 Long-term investments: Corporate debt securities Level 2 2,829 14 — 2,843 U.S. government agency securities Level 2 30,389 15 (3 ) 30,401 Municipal securities Level 2 7,632 22 — 7,654 Total $ 395,003 $ 144 $ (6 ) $ 395,141 18 November 30, 2019 Level Amortized cost Unrealized gain Unrealized loss Estimated fair value Money market funds Level 1 $ 23,834 $ — $ — $ 23,834 U.S. treasury securities Level 1 10,982 — — 10,982 Corporate debt securities Level 2 1,503 — (1 ) 1,502 U.S. government agency securities Level 2 1,402 — — 1,402 Long-term investments: Corporate debt securities Level 2 507 — (1 ) 506 Total $ 38,228 $ — $ (2 ) $ 38,226 The Company classifies its money market funds and U.S. treasury securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company classifies its investments in corporate debt securities, U.S. government agency securities, corporate commercial paper, and municipal securities as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. There were no transfers of financial instruments between valuation levels during the three and nine months ended August 31, 2020 and 2019. As of August 31, 2020 and November 30, 2019, none of the Company’s available-for-sale investments that were in an unrealized loss position had been in an unrealized loss position for more than 12 months. During the three and nine months ended August 31, 2020 and 2019, the Company did not recognize any other-than-temporary impairment losses. The Company’s short-term investments have maturities of less than one year from the respective condensed consolidated balance sheet dates. The Company’s long-term investments have maturities of between one and two years from the respective condensed consolidated balance sheet dates. 6. Commitments and contingencies Legal proceedings From time to time, the Company may be involved in legal proceedings in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. Legal fees and other costs associated with such actions are expensed as incurred. As of August 31, 2020, the Company had no outstanding, pending or threatened litigation. Indemnifications In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, suppliers and vendors, among others. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. The Company has not incurred any material costs as a result of such indemnifications and has not accrued any liabilities related to such obligations in these condensed consolidated financial statements as management believes such liability is immaterial. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s condensed consolidated financial statements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements. However, the Company currently has directors’ and officers’ insurance that reduces its exposure and may enable the Company to recover a portion of any future amounts paid. 19 Operating leases The Company leases office and laboratory facilities in San Francisco, California under a lease agreement. The original lease term was scheduled to end 60 months following the Company’s full occupancy of the leased premises, which occurred in April 2015. In October 2015, the Company entered into a second lease agreement for additional space in the same building as its existing office and laboratory facilities. In November 2017, the Company entered into an amendment to its original lease agreement that combined the Company’s two leases into a single lease agreement and extended the term of the lease agreement through April 30, 2025. The Company is required to pay base rent plus the tenant’s proportionate share of operating expenses as defined in the lease agreement. Under the terms of the lease agreement, the Company paid the landlord security deposits totaling $91,000 and issued a letter of credit to the landlord in the amount of $70,000, which is collateralized by a restricted deposit of $70,000. In June 2020, the Company entered into a new lease agreement for additional space in the same building as the Company’s existing office for a 14-month term ending on July 31, 2021. In December 2015, the Company entered into its first sublease agreement under which a portion of the Company’s leased space is subleased to another tenant. The term of the sublease, which was originally scheduled to end on December 31, 2017, was extended through December 31, 2018 as the result of an amendment executed in November 2017. The sublessee defaulted on this sublease agreement in August 2018, upon which a new creditor negotiated a second amendment to sublease dated October 2018 and the sublease agreement became a month to month agreement that ended in February 2019. The Company entered into its second sublease agreement with a different tenant in November 2018, which was subsequently amended in March 2019 to increase the size of the space. The term of the second sublease ended in August 2019. Rent expense and sublease income was as follows (in thousands): Three Months Ended August 31, Nine Months Ended August 31, 2020 2019 2020 2019 Rent expense under operating leases $ 782 $ 764 $ 2,244 $ 2,230 Sublease income — (65 ) — (311 ) Net rent expense $ 782 $ 699 $ 2,244 $ 1,919 Future minimum lease payments under the Company’s lease agreement as of August 31, 2020 were as follows (in thousands): Year ending November 30, Operating Leases 2020 (remaining 3 months) $ 830 2021 3,332 2022 3,337 2023 3,438 2024 3,541 Thereafter 1,493 Total minimum lease payments $ 15,971 7. Common stock The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue up to 500,000,000 and 65,000,000 shares of $0.001 par value common stock as of August 31, 2020 and November 30, 2019, respectively. Common stockholders are entitled to dividends when and if declared by the Company’s board of directors, subject to the prior rights of the preferred stockholders. The holder of each share of common stock is entitled to one vote. The common stockholders voting as a class are entitled to elect one member to the Company’s board of directors. As of August 31, 2020, no dividends have been declared. 20 C ommon stock reserved for future issuance, on an as-if converted basis , as of August 31, 2020 and November 30, 2019 , consists of the following and ha s been adjusted for the 1-for-3 reverse stock split : August 31, November 30, 2020 2019 Conversion of redeemable convertible preferred stock — 12,813,887 Issuance of options under stock option plan 3,460,677 1,913,792 Shares available for future stock option grants 3,982,545 412,204 Shares available for issuance under employee stock purchase plan 730,000 — Total common stock reserved for future issuance 8,173,222 15,139,883 8. Redeemable convertible preferred stock The Company’s Certificate of Incorporation, as amended, authorizes the Company to issue zero and 48,441,667 shares of redeemable convertible preferred stock as of August 31, 2020 and November 30, 2019, respectively, with a par value of $0.001 per share. Designated and outstanding redeemable convertible preferred stock and its principal terms were as follows at November 30, 2019 (in thousands, except share amounts): Shares authorized Shares issued and outstanding Liquidation value Net carrying value Series A-1 1,800,000 600,000 $ 900 $ 892 Series A-2 6,625,000 2,208,332 5,300 5,209 Series B 35,150,000 8,383,333 25,150 25,100 Series C 4,866,667 1,622,222 17,033 16,994 48,441,667 12,813,887 $ 48,383 $ 48,195 In March 2020, the Company issued 9,431,364 shares of Series D redeemable convertible preferred stock at an issuance price of $12.75 per share, resulting in net proceeds of $119.9 million. The Series D redeemable convertible preferred stock had a liquidation price per share equal to the original issue price per share. Immediately prior to the closing of the IPO in July 2020, all shares of redeemable convertible preferred stock then outstanding, including 9,431,364 shares of Series D redeemable convertible preferred stock, converted into 22,245,251 shares of common stock. There were no shares of redeemable convertible preferred stock outstanding as of August 31, 2020. The redeemable convertible preferred stock was recorded in mezzanine equity because while it was not mandatorily redeemable, it would have become redeemable at the option of the preferred stockholders upon the occurrence of a deemed liquidation event that was considered not solely within the Company’s control. 9. Stock-based compensation 2020 Equity Incentive Plan In July 2020, the Company’s board of directors approved, and the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan). The 2020 Plan became effective on July 22, 2020. The 2020 Plan provides for the granting of stock options, stock appreciation rights (SARs), restricted stock awards (RSAs), restricted stock units (RSUs), performance awards and stock bonus awards to employees, directors, consultants, independent contractors and advisors of the Company. Under the 2020 Plan, the Company generally grants stock-based awards with service-based vesting conditions only. Options granted typically vest over a four-year period but may be granted with different vesting terms. In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the total combined voting power of all classes of stock, the exercise price shall be no less than 110% of the fair value per share on the date of grant, and the award shall expire five years from the date of grant. In the case of all other stock options, the per share exercise price shall be no less than 100% of the fair value per share on the date of grant. Following the effectiveness of the 2020 Plan, the Company ceased making grants under the 2012 Equity Incentive Plan (the 2012 Plan). However, the 2012 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2012 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2012 Plan will be available for issuance under the 2020 Plan. 21 As of August 31, 2020 , there were 3, 982 , 545 shares of common stock reserved for future issuance pu rsuant to the 2020 Plan. 2012 Equity Incentive Plan In April 2012, the Company’s board of directors approved, and the Company adopted the 2012 Plan. The 2012 Plan provides for the granting of stock options, SARs, RSAs, and RSUs to employees, directors, consultants and advisors of the Company. Options granted under the 2012 Plan generally vest over four years. Options granted under the 2012 Plan may, but need not, be exercisable immediately, with any shares issued on exercise being subject to the Company’s right of repurchase. As of August 31, 2020, there were no shares of common stock reserved for issuance pursuant to the 2012 Plan. Activity under the 2020 Plan and 2012 Plan is set forth below and has been adjusted for the 1-for-3 reverse stock split (in thousands, except per share data): Number of options outstanding Weighted- average exercise price Weighted- average contractual life (in years) Aggregate intrinsic value (1) Balances as of November 30, 2019 1,913,792 $ 1.46 0.38 $ 762 Additional shares authorized — Options granted 2,078,576 8.74 Options exercised (456,460 ) 2.07 Options forfeited (75,231 ) 3.62 Shares repurchased — Balances as of August 31, 2020 3,460,677 $ 5.71 9.00 $ 61,228 Options vested and expected to vest as of August 31, 2020 (2) 3,625,569 $ 5.61 8.98 $ 64,493 Options exercisable as of August 31, 2020 2,993,112 $ 4.92 8.89 $ 55,306 (1) The aggregate intrinsic values were calculated as the pre-tax difference between the exercise price of stock options and the quoted market price of the Company’s common stock on August 31, 2020 for all in-the-money stock options. (2) Certain stock options granted by the Company prior to the date of IPO are exercisable at the date of grant, with unvested shares subject to repurchase by the Company in the event of voluntary or involuntary termination of employment of the stockholder. Such exercises are recorded as a liability in the condensed consolidated balance sheets and reclassified into equity as the options vest. As of August 31, 2020, a total of 164,892 share of common stock were subject to repurchase by the Company at the lower of (i) the fair market value of such shares on the date of repurchase, or (ii) the original exercise price of such shares. The corresponding exercise value of $0.6 million as of August 31, 2020 is recorded in share-based compensation liability. 2020 Employee Stock Purchase Plan In July 2020, the Company’s board of directors adopted the 2020 Employee Stock Purchase Plan (the 2020 ESPP) that became effective upon the date of the IPO in order to enable eligible employees to purchase shares of common stock with accumulated payroll deductions. The 2020 ESPP is intended to qualify under Section 423 of the Internal Revenue Code, as amended. Under the 2020 ESPP, eligible employees are offered the option to purchase shares of common stock at a discount over a series of offering periods. Each offering period may consist of one or more purchase periods. The purchase price for shares of common stock purchased under the 2020 ESPP will be 85% of the lesser of the fair market value of the Company’s common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of each purchase period in the applicable offering period. As of August 31, 2020, there were 730,000 shares of common stock reserved for issuance pursuant to the 2020 ESPP. The first offering period commenced as of July 23, 2020, the date on which the Company’s registration statement on Form S-1 relating to its IPO of common stock became effective, and it will end on February 15, 2021. The first purchase period will be the same as the first offering period and the first purchase date will be the last trading day of the purchase period, which is February 12, 2021. 22 The following table sets forth stock-based compensation expense related to stock options and ESPP that is included in the Company’s condensed consolidated statements of operations (in thousands) : Three Months Ended August 31, Nine Months Ended August 31, 2020 2019 2020 2019 Research and development $ 566 $ 79 $ 930 $ 220 General and administrative 549 57 835 123 Total stock-based compensation $ 1,115 $ 136 $ 1,765 $ 343 As of August 31, 2020, the total compensation cost related to stock-based awards not yet recognized was $12.5 million, which is expected to be amortized on a straight-line basis over the weighted-average remaining vesting period of approximately 3.48 years. 10. Defined contribution plan The Company sponsors a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the 401(k) Plan), which provides for the Company to make discretionary matching or discretionary annual contributions to the 401(k) Plan, for its employees. Substantially all of the Company’s employees are eligible to participate. Employees may contribute a percentage of their annual compensation to the plan, subject to statutory limitations. The Company made contributions to the 401(k) Plan during the three and nine months ended August 31, 2020 and 2019. The Company recorded contribution expense of $57,000 and $39,000 during the three months ended August 31, 2020 and 2019, respectively, and $0.3 million and $0.3 million during the nine months ended August 31, 2020 and 2019, respectively. 11. Income Taxes On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss (NOL) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in taxable years 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Any tax benefit as a result of the CARES Act is primarily due to the carryback of NOLs to prior taxable years and increased interest expense deductions. In the second fiscal quarter of 2020, the Company filed a refund claim of $15.7 million to carryback its NOLs generated in the fiscal year ended November 30, 2018, and the Company intends to file an additional refund claim to carryback its NOLs generated in the fiscal year ended November 30, 2019 to recover an additional $3.9 million of income tax. Additionally, as a result of the CARES Act, the Company anticipates its NOL carryback claims will displace certain research and development credits that were originally used to offset previous tax expense. As a result, the Company recorded a discrete income tax benefit of $20.6 million, which consist of the carryback claims and the reversal of the uncertain tax liabilities, in the condensed statement of operations for the nine months ended August 31, 2020. During the third fiscal quarter of 2020, the Company received cash for the first refund claim of $16.3 million including an interest income of $567,000, leaving the remaining income tax receivable of $3.9 million for the anticipated tax refund claims on the condensed consolidated balance sheet as of August 31, 2020. For the three months ended August 31, 2020 and 2019, the Company recorded a current income tax expense of $0 and $10,000, respectively. For the nine months ended August 31, 2020 and 2019, the Company recorded an income tax benefit of $20.6 million and a current income tax expense of $29,000, respectively. Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of the deferred tax assets is dependent upon future taxable income, the amount, if any, and timing of which are uncertain. The Company had generated losses since inception and has established a valuation allowance to offset deferred tax assets as of August 31, 2020 and November 30, 2019 due to the uncertainty of realizing future tax benefits from its NOL carryforwards and other deferred tax assets. The Company files income tax returns in the United States and in the states of California and New Jersey. The Internal Revenue Service (IRS) commenced an examination of the Company’s U.S. income tax return for the years ended December 31, 2016 and November 30, 2017 that is anticipated to be completed in 2021. In 2019, the IRS gave the Company a proposed adjustment denying a portion of the Company’s research and development (R&D) credits. The Company did not agree with the IRS’s position. However, pursuant to a measurement analysis the Company recorded an unrecognized tax benefit related to the 2016 and 2017 R&D credits. In September 2020, the Company and the IRS reached a settlement on the R&D credit issue. As a result, the Company removed the associated unrecognized tax benefit and decreased its R&D credit carryforward. See Note 14, “Subsequent events” for details. Additionally, the California Franchise Tax Board (the FTB) initiated an examination of the Company’s California tax return for the years ended December 31, 2015 and 2016. As of the issuance date of these condensed consolidated financial statements, the FTB has 23 not yet issued any assessments. T he Company’s tax years will remain open for ex amination by the federal and state authorities for three and four years, respectively, from the date of utilization of any NOL or credits. In the second fiscal quarter of 2020, the Company reclassified its liability for uncertain tax positions on the condensed consolidated balance sheet against its deferred tax asset balance, with an adjustment to the valuation allowance for deferred taxes for the same amount, as a result of the impact of the CARES Act upon the Company’s NOL carryback claims. Due to the Company’s NOL carryback claims, any federal audit settlements are recorded as adjustments to the Company’s R&D credit carryforwards and NOL balances instead of a cash tax payment. As of August 31, 2020 and November 30, 2019, there are no tax benefits included in the balance of unrecognized tax benefits that, if recognized, would affect the effective tax rate. 12. Net loss per share The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data): Three Months Ended August 31, Nine Months Ended August 31, 2020 2019 2020 2019 Numerator: Net loss $ (18,517 ) $ (2,427 ) $ (23,328 ) $ (8,180 ) Denominator: Weighted-average number of shares outstanding, basic and diluted 31,383,936 3,667,335 27,688,972 3,433,809 Net loss per share attributable to common stockholders, basic and diluted $ (0.59 ) $ (0.66 ) $ (0.84 ) $ (2.38 ) The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive: Three and Nine Months Ended August 31, 2020 2019 Redeemable convertible preferred stock on an as-converted basis — 12,813,887 Options to purchase common stock 3,460,677 1,803,136 Options early exercised subject to vesting 164,892 146,441 Shares expected to be purchased under employee stock purchase plan 62,104 — Total 3,687,673 14,763,464 13. Related party transactions As of August 31, 2020 and November 30, 2019, post-acquisition of Celgene, BMS owned 1,622,222 shares of the Company’s common stock and 1,622,222 shares of the Company’s Series C redeemable convertible preferred stock, respectively. For the three months ended August 31, 2020 and 2019, the Company recorded collaboration revenue of $0 and $9.7 million, respectively, and for the nine months ended August 31, 2020 and 2019, the Company recorded collaboration revenue of $0 and $28.4 million, respectively. As of August 31, 2020 and November 30, 2019, deferred revenue related to the Celgene agreement was $0. In June 2019, the Celgene Agreement was terminated in its entirety with no further payments from Celgene and no remaining deliverables from the Company. See Note 3, “Collaboration agreements—Celgene (a related party)” for a discussion of the Celgene Agreement. 14. Subsequent events In 2019, the IRS gave the Company a proposed adjustment denying a portion of the Company’s R&D credits. The amount of a proposed adjustment was $0.8 million and $0.9 million for 2016 and 2017, respectively. On September 21, 2020, the Company participated in a Fast Track settlement, a voluntary mediation program offered by the IRS, and agreed to accept a reduction of $0.6 million and $0.5 million for the 2016 and 2017 R&D credits, respectively. Accordingly, the Company has decreased the amount of its R&D credit carryforward by $1.1 million and recorded a decrease to the associated unrecognized tax benefit with an offset to the valuation allowance for deferred taxes. The settlement did not result in adjustments to the provision for income taxes. 24